Loading... (0%)
About liver disease

GENFIT: A COMPREHENSIVE APPROACH TO NASH

Facilitate identification and referrals of NASH patients.
LEARN MORE
Phase 3 study of elafibranor in NASH with fibrosis is currently enrolling patients around the world.
LEARN MORE

COMPANY LIFE

GENFIT is a biopharmaceutical company dedicated to high unmet medical needs.
Learn more
Find out our about current job opportunities or submit your spontaneous application explaining your project.
LEARN MORE

DOCUMENTATION

The NASH Education Program™

Health prevention, medical education, dissemination of relevant information
related to NASH disease

ACCESS WEBSITE
Press releases
  • GENFIT: Positive Phase 2 Results from Study of Elafibranor in Primary Biliary Cholangitis
    12/06/2018
  • GENFIT: Launch of a U.S. Phase 2 investigator-initiated study with nitazoxanide in patients with NASH-induced fibrosis
    12/03/2018
  • GENFIT announces plans to conduct registered Public Offering in the United States
    11/19/2018
Events
felis elit. Lorem leo. dictum mattis suscipit accumsan amet, in dolor quis